{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:32:08Z","timestamp":1782300728915,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kisupplements.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Supplements"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.kisu.2021.11.008","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T05:03:44Z","timestamp":1647579824000},"page":"69-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists\u2014unmet needs and underserved patient cohorts"],"prefix":"10.1016","volume":"12","author":[{"given":"Murray","family":"Epstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kisu.2021.11.008_bib1","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.008_bib2","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.008_bib3","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.008_bib4","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.008_bib5","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2214-109X(13)70150-5","article-title":"Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000","volume":"2","author":"Piel","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.kisu.2021.11.008_bib6","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle cell disease","volume":"376","author":"Piel","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.008_bib7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/ckj\/sfx027","article-title":"Sickle cell disease and albuminuria: recent advances in our understanding of sickle cell nephropathy","volume":"10","author":"Audard","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kisu.2021.11.008_bib8","doi-asserted-by":"crossref","first-page":"S28S36","DOI":"10.1016\/j.annemergmed.2020.08.009","article-title":"Trends in sickle cell disease-related mortality in the United States, 1979 to 2017","volume":"76","author":"Payne","year":"2020","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.kisu.2021.11.008_bib9","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3285","article-title":"Hydroxyurea use for sickle cell disease among Medicaid-enrolled children","volume":"144","author":"Brousseau","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.kisu.2021.11.008_bib10","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease","volume":"115","author":"Quinn","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.kisu.2021.11.008_bib11","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1007\/s00467-010-1736-2","article-title":"Sickle cell nephropathy: challenging the conventional wisdom","volume":"26","author":"Becker","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kisu.2021.11.008_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/ncpneph1008","article-title":"Sickle cell disease and the kidney","volume":"5","author":"Scheinman","year":"2009","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.kisu.2021.11.008_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrneph.2015.8","article-title":"Sickle cell disease: renal manifestations and mechanisms","volume":"11","author":"Nath","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kisu.2021.11.008_bib14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1681\/ASN.2019050502","article-title":"Kidney function decline among Black patients with sickle cell trait and sickle cell disease: an observational cohort study","volume":"31","author":"Olaniran","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2021.11.008_bib15","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/pbc.24557","article-title":"Sickle cell disease related mortality in the United States (1999-2009)","volume":"60","author":"Hamideh","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.kisu.2021.11.008_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236998","article-title":"Outcomes following kidney transplantation in patients with sickle cell disease: the impact of automated exchange blood transfusion","volume":"15","author":"Willis","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2021.11.008_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/MD.0b013e3181ca59b6","article-title":"Glomerular lesions in patients with sickle cell disease","volume":"89","author":"Maigne","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.kisu.2021.11.008_bib18","series-title":"Angiotensin II Receptor Antagonists","first-page":"295","article-title":"AT1 receptor antagonists and the kidney","author":"Gansevoort","year":"2001"},{"key":"10.1016\/j.kisu.2021.11.008_bib19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0002-9343(99)80341-6","article-title":"Enalapril reduces the albuminuria of patients with sickle cell disease","volume":"98","author":"Aoki","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.kisu.2021.11.008_bib20","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1056\/NEJM199204023261402","article-title":"Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme","volume":"326","author":"Falk","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.008_bib21","first-page":"CD009191","article-title":"Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease","volume":"2015","author":"Sasongko","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kisu.2021.11.008_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0009-9236(96)90161-7","article-title":"Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema","volume":"60","author":"Brown","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.kisu.2021.11.008_bib23","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1177\/1060028018779082","article-title":"A\u00a0review of ACE inhibitors and ARBs in Black patients with hypertension","volume":"52","author":"Helmer","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.kisu.2021.11.008_bib24","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40615-020-00853-0","article-title":"Ethnic prevalence of angiotensin-converting enzyme deletion (D) polymorphism and COVID-19 risk: rationale for use of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers","volume":"8","author":"Sarangarajan","year":"2021","journal-title":"J\u00a0Racial Ethn Health Disparities"},{"key":"10.1016\/j.kisu.2021.11.008_bib25","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.12024","article-title":"High one-year mortality in adults with sickle cell disease and end-stage renal disease","volume":"159","author":"McClellan","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.kisu.2021.11.008_bib26","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7326\/0003-4819-115-8-614","article-title":"Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality","volume":"115","author":"Powars","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kisu.2021.11.008_bib27","first-page":"174","article-title":"End-stage sickle cell nephropathy: determinants of reduced survival of patients on long-term hemodialysis","volume":"15","author":"Saxena","year":"2004","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.kisu.2021.11.008_bib28","first-page":"614610","article-title":"Outcome and challenges of kidney transplant in patients with sickle cell disease","volume":"2013","author":"Okafor","year":"2013","journal-title":"J\u00a0Transplant"},{"key":"10.1016\/j.kisu.2021.11.008_bib29","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/ndt\/gfs585","article-title":"Improved survival among sickle cell kidney transplant recipients in the recent era","volume":"28","author":"Huang","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2021.11.008_bib30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2215\/CJN.02720320","article-title":"Mortality and access to kidney transplantation in patients with sickle cell disease-associated kidney failure","volume":"16","author":"Bae","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2021.11.008_bib31","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1053\/j.ajkd.2019.09.003","article-title":"US renal data system 2019 annual data report: epidemiology of kidney disease in the United States","volume":"75","author":"Saran","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2021.11.008_bib32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrneph.2012.33","article-title":"Statins in the management of dyslipidemia associated with chronic kidney disease","volume":"8","author":"Epstein","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kisu.2021.11.008_bib33","doi-asserted-by":"crossref","unstructured":"Epstein M, Freundlich M. The intersection of mineralocorticoid receptor (MR) activation and the FGF23\u2013Klotho cascade. A duopoly that promotes renal and cardiovascular injury. Nephrol Dial Transplant. 2022;37:211\u2013221.","DOI":"10.1093\/ndt\/gfab254"},{"key":"10.1016\/j.kisu.2021.11.008_bib34","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1007\/s00467-020-04843-6","article-title":"Fibroblast growth factor 23-Klotho and hypertension: experimental and clinical mechanisms","volume":"36","author":"Freundlich","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kisu.2021.11.008_bib35","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/ndt\/gfy006","article-title":"Fibroblast growth factor 23 is induced by an activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts","volume":"33","author":"Leifheit-Nestler","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2021.11.008_bib36","doi-asserted-by":"crossref","first-page":"12398","DOI":"10.1038\/s41598-018-30098-1","article-title":"Cardiovascular interactions between fibroblast growth factor-23 and angiotensin II","volume":"8","author":"Pi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.kisu.2021.11.008_bib37","doi-asserted-by":"crossref","first-page":"649921","DOI":"10.3389\/fphys.2021.649921","article-title":"Aldosterone is positively associated with circulating FGF23 levels in chronic kidney disease across four species, and may drive FGF23 secretion directly","volume":"12","author":"Radloff","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.kisu.2021.11.008_bib38","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1093\/ndt\/gfy315","article-title":"Fibroblast growth factor 23 is associated with fractional excretion of sodium in patients with chronic kidney disease","volume":"34","author":"Xu","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2021.11.008_bib39","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bbadis.2017.09.029","article-title":"Klotho protects the heart from hyperglycemia-induced injury by inactivating ROS and NF-kappaB-mediated inflammation both in\u00a0vitro and in\u00a0vivo","volume":"1864","author":"Guo","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.kisu.2021.11.008_bib40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bone.2017.01.017","article-title":"Potential application of klotho in human chronic kidney disease","volume":"100","author":"Neyra","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.kisu.2021.11.008_bib41","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s11255-016-1319-7","article-title":"Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis","volume":"48","author":"Lu","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.kisu.2021.11.008_bib42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.kisu.2021.11.008_bib43","doi-asserted-by":"crossref","first-page":"105859","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders\u2014new perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.kisu.2021.11.008_bib44","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kisu.2021.11.008_bib45","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kisu.2021.11.008_bib47","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1161\/CIRCRESAHA.121.318093","article-title":"Obesity, adipose tissue and vascular dysfunction","volume":"128","author":"Koenen","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.kisu.2021.11.008_bib48","doi-asserted-by":"crossref","unstructured":"Epstein M. Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: an extraordinary paradigm shift. Kidney Int Suppl. 2022;12:1\u20136.","DOI":"10.1016\/j.kisu.2021.11.007"},{"key":"10.1016\/j.kisu.2021.11.008_bib49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/MNH.0000000000000384","article-title":"The regulation of aldosterone secretion by leptin: implications in obesity-related cardiovascular disease","volume":"27","author":"Faulkner","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kisu.2021.11.008_bib50","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","article-title":"Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension","volume":"150","author":"Sowers","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kisu.2021.11.008_bib51","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41371-020-00467-3","article-title":"The mineralocorticoid receptor\u2014an emerging player in metabolic syndrome?","volume":"35","author":"Thuzar","year":"2021","journal-title":"J\u00a0Hum Hypertens"}],"container-title":["Kidney International Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171621000733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171621000733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:51:21Z","timestamp":1775004681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2157171621000733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2157171621000733"],"URL":"https:\/\/doi.org\/10.1016\/j.kisu.2021.11.008","relation":{},"ISSN":["2157-1716"],"issn-type":[{"value":"2157-1716","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists\u2014unmet needs and underserved patient cohorts","name":"articletitle","label":"Article Title"},{"value":"Kidney International Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2021.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}